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Aim To determine in-hospital and post-discharge mortal-
ity, readmission rates, and predictors of invasive mechan-
ical ventilation (IMV) in patients treated at intensive care 
unit (ICU) due to acute exacerbations of chronic obstruc-
tive pulmonary disease (AECOPD).
Methods A retrospective observational cohort study in-
cluded all patients treated at a respiratory ICU for AECOPD 
during one year. A total of 62 patients (41 men) with mean 
age 68.4 ± 10.4 years were analyzed for outcomes includ-
ing in-hospital and post-discharge mortality, readmission 
rates, and IMV. Patients’ demographic, hematologic, bio-
chemical data and arterial blood gas (ABG) values were re-
corded on admission to hospital. Mean duration of follow-
up time was 2.4 years.
Results Of 62 patients, 7 (11.3%) died during incident hos-
pitalization and 21 (33.9%) died during the follow-up. The 
overall 2.4-year mortality was 45.2%. Twenty nine (46.8%) 
patients were readmitted due to AECOPD. The average 
number of readmissions was 1.2. Multivariate analysis 
showed that blood pH, bicarbonate levels, low albumin, 
low serum chloride, and low hemoglobin were significant 
predictors of IMV during incident hospitalization (P < 0.001 
for the overall model fit).
Conclusion High in-hospital and post-discharge mortal-
ity and high readmission rates in our patients treated due 
to AECOPD at ICU indicate that these patients represent 
a high risk group in need of close monitoring. Our results 
suggested that anemia, hypoalbuminemia, and elevat-
ed troponin levels were risk factors for the need of IMV in 
severe AECOPD. Identification of such high-risk patients 
could provide the opportunity for administration of an ap-
propriate and timely treatment.
Anemia, hypoalbuminemia, 
and elevated troponin levels 
as risk factors for respiratory 
failure in patients with severe 
exacerbations of chronic 
obstructive pulmonary disease 
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Chronic obstructive pulmonary disease (COPD) is a major 
cause of morbidity and mortality affecting approximately 
10% of the total adult population (1,2). The natural course 
of the disease is disrupted by exacerbations, representing 
a major event for COPD management due to its negative 
impact on disease progression, health status, and quality of 
life (1,3,4). About 10% of all hospitalizations are directly or in-
directly related to COPD, which places a significant burden 
on the health care system (5). Acute COPD exacerbations 
(AECOPD) often result in worsening of respiratory failure 
or incident one. AECOPD are a common cause of intensive 
care unit (ICU) admissions of patients requiring non-invasive 
(NIV) or invasive mechanical ventilation (IMV). Long-term 
mortality of in-hospital COPD patients treated for AECOPD 
is high, with a survival rate comparable to that of a lung can-
cer (6,7). According to Intensive Care National Audit & Re-
search Centre (ICNARC) Case Mix Program Database, 23.1% 
of patients die during their stay at the ICU, and 38.8% during 
hospitalization (8). No data are available for Croatia. The ICU 
management of these high-risk patients includes ventilator 
support (NIV or IMV), inhaled bronchodilators, systemic cor-
ticosteroids, and antibiotics, but the evidence behind these 
interventions almost inadequate (9).
NIV represents an effective method for the management of 
hypercapnic respiratory failure in AECOPD. For the manage-
ment of AECOPD, apart from ICUs, NIV is today frequently 
applied in regular wards. However, NIV failure and the need 
for IMV can be expected in about a quarter of patients (10). 
Therefore, when NIV is used, it is necessary to monitor pa-
tients carefully. Identification of risk factors for NIV failure 
could help define a group of patients who require more 
stringent monitoring or additional intervention. This could 
allow for targeted interventions that could improve surviv-
al, directing medical resources cost-effectively.
The aim of our study was to determine in-hospital and 
post-discharge mortality, predictors of survival time, read-
mission rates, and NIV failure rates in COPD patients treated 
at ICU due to a high degree of respiratory failure and clini-
cal severity of AECOPD. This study was a hypothesis-gener-
ating association study for the possible predictors of poor 
outcomes, such as in-hospital and post discharge mortal-
ity, readmissions, and NIV failure, in this group of high-risk 
COPD patients, representing Level 4 of evidence (11).
METHODS
Study design
This was a retrospective observational cohort study of 
all patients treated at our ICU for AECOPD during one 
year, with the follow-up for readmissions and post-discharge 
mortality. We analyzed variables routinely collected during 
the treatment of AECOPD patients, ie, universal and easily ac-
cessible parameters. As this was a retrospective analysis of 
anonymized clinically obtained data, there was no need for 
patients to sign the informed consent. The competent Ethics 
Committee approved that in specific cases, where there was 
no data in hospital database about the death of a patient 
through the follow-up period, the patient or a family mem-
ber would be contacted by phone just for this specific infor-
mation (time of death, if any). Verbal consent was obtained 
at the time of interview before obtaining the information.
Patient selection
We included all 62 patients treated for AECOPD and subse-
quent respiratory failure at our respiratory ICU from Septem-
ber 2013 through September 2014. All patients included in 
this study had already been diagnosed with COPD accord-
ing to Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) by their physician (1). AECOPD was defined as a 
worsening in at least two of the following symptoms: cough, 
purulent sputum, and dyspnea (1). Patients were admitted 
to the ICU due to one or more of the following indications: 
persistent or worsening hypoxemia or severe or worsening 
hypercapnia despite the initial treatment, respiratory acido-
sis, or impaired consciousness (confusion, lethargy, or coma) 
due to hypercapnia. To avoid selection bias, we included all 
patients consecutively treated under this diagnosis. Patient 
data collected on admission included demographic data 
(age, sex), duration of COPD, body mass index (BMI, calcu-
lated as body mass in kilograms divided by squared body 
height in meters), and comorbidities (pneumonia, hyper-
tension, coronary heart disease, pulmonary hypertension, 
chronic pulmonary heart, cardiac decompensation, diabe-
tes, obstructive sleep apnea, psychiatric disorders, and ma-
lignancy). The duration of COPD was defined from the date 
when the patient first contacted a physician due to the prob-
lems with chronic cough, sputum, and breathlessness.
Study outcomes
The primary outcomes were in-hospital mortality and 
death during the follow-up period. As this was a retrospec-
tive study, only the date of death was available for all de-
ceased patients. Data on the cause of death were not reli-
able and accurate because, in most cases (even in-hospital 
deaths), autopsy was not performed because it is not man-
datory. The secondary outcomes were the need for read-
mission due to AECOPD during the follow-up period, the 
397Pavliša et al: Predictors of poor outcomes in severe AECOPD
www.cmj.hr
time to first readmission, and the need for IMV during inci-
dent hospitalization.
Data on the IMV and in-hospital mortality were obtained 
from patients’ hospital medical records. Mortality data af-
ter incident hospitalization and readmission data were 
obtained through telephone interviews with patients or 
members of their family or from hospital database.
Data on the predictors of study outcomes were also ob-
tained from patients’ hospital medical records, including 
demographic and clinical data and values of hematologic 
and biochemical parameters and arterial blood gases. The 
average follow-up period was 2.4 years.
Laboratory analyses
All analyzed data were extracted from patients’ hospital 
medical records. According to the in-house protocol, 2 
blood samples were taken at the time of admission. The 
first sample was arterial blood taken for blood gases analy-
sis, which was performed on ABL800 Flex (Radiometer, Co-
penhagen, Denmark) (12). The second sample was venous 
blood taken for the analysis of the following parameters: 
hematologic parameters, prothrombin time, activated par-
tial thromboplastin time, fibrinogen, D-dimer, glucose, 
urea, creatinine, bilirubin, aspartate transaminase, alanine 
transaminase, gamma glutamyl transferase, alkaline phos-
phatase, creatine kinase, lactate dehydrogenase, sodium, 
potassium, chloride, troponin T, total iron, unsaturated 
iron-binding capacity, total iron-binding capacity, ferritin, 
total serum protein, albumin, and protein electrophoresis. 
Anemia was defined according to the World Health Orga-
nization criteria, ie, as the concentration of hemoglobin 
(Hgb)<13 g/dL in men and <12 g/dL in women (13).
Treatment
Patients were treated according to GOLD recommenda-
tions for AECOPD (1). Patients were treated with 40 mg 
TAbLE 1. baseline characteristics of patients with acute exacerbation of chronic obstructive pulmonary disease in total and accord-
ing to their need for mechanical ventilation*
No. (%) of patients†
Patient characteristics total (N = 62) mechanical ventilation (n = 14) no mechanical ventilation (n = 48) P
Age on admission (years) 68.4 ± 10.4 67.4 ± 11.2 68.6 ± 10.4 0.725
Women 21 (33.9)  6 (42.9) 15 (31.9) 0.449
bMI (kg/m2) 26.19 ± 6.04 24.30 ± 4.99 26.73 ± 6.25 0.205
Duration of COPD (years) 12.6 ± 5.5 14.7 ± 6.5 11.6 ± 5.0 0.277
Comorbidities
pneumonia 33 (53.2)  7 (50.0) 26 (54.2) 0.726
heart failure 15 (24.2)  5 (35.7) 11 (22.9) 0.358
renal failure 12 (19.4)  3 (21.4)  9 (18.8) 0.851
diabetes mellitus 18 (29.0)  4 (28.6) 14 (29.2) 0.930
psychiatric disorder 15 (24.2)  3 (21.4) 12 (25.0) 0.101
malignancy  5 (8.1)  0 (0.0)  5 (10.4) 0.203
bronchiectasis  3 (4.8)  1 (7.1)  2 (4.2) 0.549
hypertension 21 (33.9)  3 (21.4) 18 (37.5) 0.244
obstructive sleep apnea  5 (8.1)  0 (0)  5 (10.4) 0.203
coronary artery disease 23 (37.1)  7 (50.0) 16 (33.3) 0.280
pulmonary heart disease 30 (48.4)  9 (64.3) 21 (43.8) 0.198
pulmonary hypertension 15 (24.2)  5 (35.7) 10 (20.8) 0.271
ICU stay (days)  7 (4 to 10) 10.5 (8 to 14)  6 (4 to 9) 0.003
Non-invasive ventilation (h) 22 (9 to 48) 15.5 (8 to 130) 22 (10 to 42) 0.783
Died 28 (45.2) 10 (71.4) 18 (37.5) 0.025
during incident hospitalization  7 (11.3)  4 (28.6)  3 (6.3) 0.020
during the follow-up time 21 (33.9)  6 (42.8) 15 (31.2) 0.419
*Abbreviations: SD – standard deviation, bMI – body mass index, COPD – chronic obstructive pulmonary disease, ICU – intensive care unit.
†Data are presented as numbers (%), medians with interquartile range (IQR), and mean with standard deviation (SD). Statistical significance for 
group comparisons was tested using χ2 or Fisher exact test for categorical variables, Mann-Whitney U test for quantitative variables presented as 
median (IQR), and Student’s t test for variables presented as mean±SD.
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of intravenous methylprednisolone, nebulized broncho-
dilators (inhaled salbutamol and ipratropium bromide), 
and theophylline. Antibiotics were used in patients with 
signs of bacterial infection present. Comorbidities, such 
as arterial hypertension, coronary heart disease, cardi-
ac decompensation, diabetes, and psychiatric disorders, 
were treated according to the principles of good clini-
cal practice. Respiratory failure was managed with oxy-







no mechanical ventilation 
(n = 48) P
Erythrocyte count (1012/L)   4.65 ± 0.84   4.04 ± 0.70   4.86 ± 0.78 0.001
Hemoglobin (g/L) 134.6 ± 21.9 116.9 ± 19.9 140.4 ± 19.5 <0.001
Hematocrit (L/L)   0.429 ± 0.073   0.370 ± 0.060   0.449 ± 0.066 <0.001
Platelet count (109/L) 256 ± 112 306 ± 146 241 ± 98 0.080
Leukocyte count (109/L)  11.5 ± 4.2  13.6 ± 4.4  11.0 ± 4.0 0.036
Neutrophils (109/L)   9.4 ± 3.8  10.6 ± 4.0   9.0 ± 3.7 0.170
Lymphocytes (109/L)   0.86 (0.50 to 1.20)   1.15 (0.5 to 1.5)   0.7 (0.42 to 1.10) 0.136
Monocytes (109/L)   0.60 (0.30 to 0.98)   0.94 (0.3 to 1.1)   0.5 (0.3 to 0.8) 0.175
Prothrombin time   0.90 ± 0.27   0.92 ± 0.24   0.89 ± 0.28 0.706
Activated partial thromboplastin time (s)  26.0 ± 5.50  25.0 (23.8 to 27.4)  25.5 (23.0 to 29.0) 0.468
Fibrinogen (s)   5.21 ± 1.90   5.49 ± 1.68   5.13 ± 1.97 0.560
D dimer (μg/mL)   1.29 (0.76 to 2.35)   1.96 (1.09 to 4.35)   1.23 (0.61 to 1.99) 0.118
Blood glucose (mmol/L)   8.8 ± 3.6   9.1 ± 4.0   8.8 ± 3.5 0.747
Urea (mg/L)   8.4 (5.5 to 11.0)   8.1 (5.5 to 10.2)   8.4 (5.5 to 11.0) 0.764
Creatinine (mg/L)  99.5 (86.0 to 133.0)  97 (66 to 112) 104 (88 to 134) 0.143
Bilirubin (μmol/L)   7 (5 to 12)   5 (3 to 6)   7 (5 to 12) 0.011
Aspartate transaminase (U/L)  23 (18 to 35)  26 (17 to 35)  23 (18 to 33) 0.764
Alanine transaminase (U/L)  21 (13 to 29)  17.5 (14 to 28)  21 (12 to 30) 0.804
Gamma glutamyl transferase (U/L)  22.5 (15.5 to 46.0)  27 (19 to 64)  22 (14 to 38) 0.242
Alkaline phosphatase (U/L)  80.2 ± 42.8  93.4 ± 55.5  76.3 ± 38.1 0.194
Creatine kinase (U/L)  64 (37 to 92)  82 (47.5 to 131.5)  59.5 (33 to 90) 0.394
Lactate dehydrogenase (U/L) 190.5 (158 to 223) 202.5 (176 to 256) 184 (154.5 to 216.5) 0.151
Potassium (mmol/L)   4.5 ± 0.6   4.3 ± 0.5   4.5 ± 0.7 0.416
Sodium (mmol/L) 139 ± 5 137 ± 5 140 ± 4 0.063
Chloride (mmol/L)  94 ± 6  91 ± 7  95 ± 5 0.019
C reactive protein (mg/L)  40.2 (11.5 to 95.2)  60.75 (22.9 to 94.3)  34.1 (8.0 to 95.2) 0.261
Total serum protein (g/L)  64.0 ± 7.1  61.4 ± 8.8  64.8 ± 6.4 0.116
Albumin (g/L)  34.8 ± 6.4  30.4 ± 6.3  36.3 ± 5.8 0.002
Troponin T (ng/mL)   0.022 (0.017 to 0.054)   0.044 (0.022 to 0.131)   0.021 (0.014 to 0.034) 0.006
Sedimentation rate (mm/h)  38.7 ± 29.3  46 ± 29  36 ± 29 0.309
Anti-thrombin 3 (%)  78.9 ± 28.6  83.8 ± 34.4  77.5 ± 27.1 0.528
Total iron (µmol/L)   7 (5 to 11)   6 (5 to 10)   8.5 (5 to 11) 0.601
Unsaturated iron-binding capacity (µmol/L)  42 ± 16  38 ± 12  43 ± 16 0.359
Total iron-binding capacity (µmol/L)  51 ± 14  46 ± 11  52 ± 14 0.211
Ferritin (ng/mL)  89.1 (27.8 to 358.2) 238.5 (60.0 to 360.2)  59.4 (26.6 to 343.0) 0.363
Alpha-1 globulin (g/L)   4.30 ± 1.03   4.9 ± 0.9   4.1 ± 1.0 0.018
Alpha-2 globulin (g/L)   8.30 ± 1.86   8.2 ± 1.7   8.3 ± 1.9 0.909
Beta globulin (g/L)   7.77 ± 1.64   7.4 ± 1.4   7.9 ± 1.7 0.444
Gamma globulin (g/L)   9.75 ± 3.80   8.1 ± 3.1  10.2 ± 3.9 0.096
A/G ratio   1.09 ± 0.22   0.98 ± 0.12   1.13 ± 0.23 0.033
*Data are presented as numbers (%), medians with interquartile range (IQR), and mean with standard deviation (SD). Statistical significance for 
group comparisons was tested using Mann-Whitney U test for quantitative variables presented as median (IQR), and Student’s t test for variables 
presented as mean±SD.
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gen supplementation, NIV or IMV, according to the indi-
vidual needs to achieve satisfactory arterial blood oxygen 
saturation of at least 88%-90% and to maintain pH with-
in the physiological range. Patients were carefully mon-
itored during treatment. NIV and IMV were also applied 
according to GOLD recommendations (1). NIV was used 
in patients with respiratory acidosis, severe dyspnea with 
clinical signs suggestive of respiratory muscle fatigue, in-
creased work of breathing, and persistent hypoxemia de-
spite supplemental oxygen therapy. In patients who were 
unable to tolerate NIV or in patients with NIV failure, IMV 
was initiated. Also, IMV was used in patients after cardiac 
or respiratory arrest, those unable to remove mucus secre-
tion, those who had severe hemodynamic instability with-
out response to fluids and vasoactive drugs, and patients 
with severe cardiac arrhythmias (1).
Statistical analysis
Categorical variables were presented as numbers and pro-
portions (%). Quantitative variables were presented as 
means and standard deviations (SD) or as medians with in-
terquartile range (IQR), depending on the normality of distri-
bution tested using Kolmogorov-Smirnov test. Differences 
between groups for categorical variables were evaluated us-
ing the χ2 test or Fisher exact test. Differences for quantita-
tive variables were evaluated using Student’s t test or Mann-
Whitney U-test depending on the distribution. Univariate 
regression analysis was performed to identify variables as-
sociated with outcome measures at P < 0.10. These variables 
were used to build multivariable models defining predictors 
and prediction models for outcome measures including the 
need for IMV, readmission during follow-up, time to next 
hospitalization, and survival time after incident hospitaliza-
tion, using stepwise multivariable logistic regression analy-
sis. Stepwise Cox proportional hazard regression was used 
for survival analysis. Statistical analyses were done using STA-
TISTICA version 12 (StatSoft, Inc., OK, USA).
RESULTS
The analyses included all 62 patients admitted to ICU for 
the treatment of severe AECOPD. Patients in need for IMV 
were of comparative age, sex, and body composition (Ta-
ble 1). The duration of COPD was 3 years longer in IMV 
group of patients, but this difference did not reach statis-
tical significance. Comparable distribution regarding co-
morbidities was found for both groups, with a comparable 
NIV duration between the groups, but with a significantly 
longer ICU stay in IMV group.
TAbLE 3. Arterial blood gases on initial and following day according to the need for mechanical ventilation (N = 62)*
Parameter values†
Parameter total (N = 62) mechanical ventilation (n = 14) no mechanical ventilation (n = 48) P
pH on admission day   7.31 ± 0.09   7.30 ± 0.10   7.31 ± 0.08 0.594
HCO3 on admission day (mmol/L)  37.4 ± 8.6  40.7 ± 8.0  36.6 ± 8.7 0.127
Paco2 on admission day (mmHg)  74.6 ± 22.2  82.2 ± 21.6  73.3 ± 21.9 0.196
Pao2 on admission day (mmHg)  45.6 ± 19.4  51.4 ± 33.2  44.2 ± 13.9 0.979
Sao2 on admission day (%)  68.0 ± 18.6  65.8 ± 21.4  68.9 ± 18.3 0.615
Pao2/FiO2 on admission day 173.0 ± 52.7 178.5 ± 74.7 171.2 ± 44.0 0.880
pH on second day   7.35 ± 0.07   7.38 ± 0.09   7.34 ± 0.07 0.149
pH change   0.04 ± 0.10   0.08 ± 0.15   0.03 ± 0.08 0.054
HCO3 on second day (mmol/L)  36.8 ± 8.8  38.4 ± 9.8  36.5 ± 8.5 0.501
HCO3 change (mmol/L)   1 (-4 to 4)   0 (-5 to 2)   1 (-2 to 5) 0.504
Paco2 on second day (mmHg)  69.5 ± 19.8  67.1 ± 14.3  70.9 ± 20.9 0.535
Paco2 change (mmHg)   -2.5 (-15.5 to 5)   -5 (-24 to 1)   0.5 (-11 to 6) 0.032
Pao2 on second day (mm Hg)  69.4 ± 15.1  71.4 ± 15.4  68.9 ± 15.3 0.607
Pao2 change (mm Hg)  24.1 ± 23.9  20.8 ± 37.7  25.0 ± 19.2 0.609
Sao2 on second day (%)  90.3 ± 6.0  91.4 ± 5.1  89.9 ± 6.3 0.432
Sao2 change (%)  22.7 ± 18.9  25.7 ± 22.8  21.5 ± 17.9 0.482
Pao2/FiO2 on second day 220.8 ± 52.1 217.2 ± 47.2 221.8 ± 54.0 0.820
*Abbreviations: HCO3 – bicarbonate, Paco2 – partial pressure of carbon dioxide, Pao2 – partial pressure of oxygen, Sao2 - oxygen saturation, Pao2/FiO2 – 
ratio of arterial oxygen partial pressure to fractional inspired oxygen.
†Data are presented as medians with interquartile range (IQR) and means with standard deviation (SD). Statistical significance for group compari-
sons was tested using Mann-Whitney U test for quantitative variables presented as median (IQR) and Student’s t test for variables presented as 
mean±SD.
CLINICAL SCIENCE400 Croat Med J. 2017;58:395-405
www.cmj.hr
Patients receiving IMV had significantly lower red blood 
cell counts, hemoglobin, and hematocrit values and higher 
white blood cell counts, but their platelet, neutrophil, lym-
phocyte, and monocyte counts were not significantly high-
er (Table 2). There were no significant differences between 
the groups for coagulation factors, serum glucose, and renal 
and liver function markers, except for bilirubin, which was 
significantly lower in IMV group. Significantly lower values 
were found for chloride serum levels, albumin, A/G ratio, and 
significantly higher for troponin, and alpha1 globulin.
Arterial blood gases on the initial and second day of inci-
dent hospitalization showed no significant differences be-
tween the groups, although Paco2 was higher in the IMV 
group on the day of admission and showed a significantly 
greater fall on the second day, as expected (Table 3).
Outcomes
Of 62 patients treated at ICU due to AECOPD, 7 (11.3%) 
died during incident hospitalization and 21 (33.9%) died 
during the follow-up (Table 1); thus, the overall 2.4-year 
mortality was 45.2%. A multivariate model showed that the 
survival time after incident hospitalization was indepen-
dently associated with absolute number of monocytes, 
serum LDH level, comorbid cancer, hypertension, and BMI 
TAbLE 4. Significant predictors for the survival time after incident hospital admission (Cox proportional hazard regression analysis)*
Covariate b SE Wald P Exp(b) 95% CI of Exp(b)
Monocyte count   0.584 0.204  8.209  0.004  1.792 1.202 to 2.671
Lactate dehydrogenase   0.007 0.003  6.674  0.010  1.007 1.002 to 1.012
Cancer   2.774 0.733 14.366 <0.001 16.020 3.817 to 67.239
Arterial hypertension -1.736 0.727  5.710  0.017  0.176 0.042 to 0.732
BMI -0.200 0.047 18.173 <0.001  0.818 0.746 to 0.897
*Abbreviations: SE – standard error, CI – confidence interval, bMI – body mass index.
TAbLE 5. Significant predictors for the time to next hospitalization (Cox proportional hazard regression analysis)*
Covariate b SE Wald P Exp(b) 95% CI of Exp(b)
Paco2 on admission day   0.031 0.015  4.099 0.042 1.031 1.001 to 1.062
pH on a second day -11.090 3.988  7.735 0.005 0.000 6.15*10−9 to 0.038
Fibrinogen  -0.519 0.162 10.294 0.001 0.595 0.433 to 0.817
Total serum protein  -0.134 0.043  9.921 0.002 0.874 0.804 to 0.951
Alfa2 globulin   0.554 0.210  6.923 0.009 1.739 1.152 to 2.627
*Abbreviations: SE – standard error, CI – confidence interval.
TAbLE 6. Significant predictors for the number of hospitalizations after the incident one*
Predictor Estimate Standard Error Wald 95% CI P
Intercept -14.981 5.543  7.305 -25.844 to -4.117  0.007
Age at admission  -0.029 0.014  4.263  -0.056 to -0.001  0.039
Neutrophils  -0.202 0.056 12.929  -0.311 to -0.092 <0.001
No CAD    0.586 0.199  8.652    0.196 to 0.977  0.003
Sodium    0.137 0.039 12.111    0.060 to 0.213 <0.001
Bilirubin  -0.086 0.041  4.288  -0.166 to -0.005  0.038
*Abbreviations: CI – confidence interval, CAD – coronary artery disease.
TAbLE 7. Significant predictors for mechanical ventilation*
Variable Coefficient Standard error Wald P Odds ratio 95% CI
pH -14.137 6.900 4.197 0.041  0.001 10−14 to 0.54
HCO3   0.142 0.074 3.652 0.056  1.15 1.00 to 1.33
Low albumin   3.877 1.503 6.658 0.010 48.30 2.54 to 918.57
Low chloride   2.169 1.151 3.549 0.059  8.75 0.92 to 83.58
Low hemoglobin   3.759 1.464 6.592 0.010 42.91 2.43 to 756.37
*Abbreviations: CI – confidence interval, HCO3 – bicarbonate.
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(chi2 = 40.080, df = 5, P < 0.001 for the overall model fit, Cox 
proportional hazard regression; Table 4).
Twenty nine (46.8%) patients had one or more readmis-
sions after discharge. A multivariate model showed that 
time to readmission was independently associated with 
Paco2 on admission day, pH on the second day, levels of 
fibrinogen, proteins and alpha 2 globulins (chi2 = 20.161, 
df = 5, P = 0.001 for the overall model fit, Cox proportional 
hazard regression; Table 5). According to the multivariate 
model, age on admission, absolute number of neutrophils, 
no coronary artery disease (CAD), levels of sodium, and bil-
irubin were significantly associated with the number of re-
admissions during the median follow-up time of 2.4 years 
(Table 6).
The need for IMV during the incident hospitalization was 
present in 14 (22.6%) patients. Multivariate analysis re-
vealed five independent variables as significant predictors 
for IMV during incident hospitalization. These variables in-
cluded blood pH and bicarbonate levels, low albumin, low 
serum chloride, and low hemoglobin (Table 7). The mod-
el has an area under the curve (AUC) of 0.951 (95% con-
fidence interval (CI), 0.856 to 0.991), sensitivity of 76.92% 
(95% CI, 49.74%-91.82%), specificity of 97.62% (95% CI, 
87.68%-99.58%), positive predictive value (PPV) of 90.91% 
(95% CI, 62.26%-98.38%), negative predictive value (NPV) 
of 93.18% (95% CI, 81.77%-97.65%), and diagnostic accura-
cy of 92.73% (95% CI, 82.74%-97.14%) (chi2 = 29.609, df = 5, 
P < 0.001 for the model).
DISCUSSION
We determined the predictors of poor outcomes in pa-
tients treated for severe AECOPD with respiratory failure in 
ICU of a tertiary respiratory medical center. As expected for 
such a high-risk group of patients, we found a high overall 
mortality, with an in-hospital mortality of 11.3% and post 
discharge mortality of 38.2% during an average follow-
up period of 2.4 years. The possible independent predic-
tors for overall survival, readmission risk, and respiratory 
failure with the necessity for IMV in our AECOPD patients 
with high mortality risk were hypoalbuminemia or anemia, 
which could be modifiable or treatable. Connors et al (13) 
reported similar in-hospital mortality and two-year mor-
tality in patients hospitalized due to AECOPD and treated 
in open wards and ICU. Gunen et al (14) prospectively fol-
lowed patients all hospitalized due to AECOPD for three 
years after discharge and reported similar percentages of 
overall in-hospital mortality, two-year mortality, and three-
year mortality, but found that the subgroup of patients 
hospitalized in ICU had in-hospital mortality of 27%. Clini-
cal characteristics of our patients regarding Paco2, pH, age, 
duration of COPD were worse than those in Gunen’s group 
of patients (14), reflecting a more severe degree of respi-
ratory failure and clinical condition. According to ICNARC 
Case Mix Program Database, 23.1% of patients who need 
treatment in ICU die during their stay in the ICU, and 38.8% 
during hospitalization (6). Results of that study showed 
lower average Paco2 and pH than those found in our pa-
tients, which could indicate acute onset of deterioration 
(8). Seneffe et al (15) found in-hospital mortality of 24% 
in patients treated in ICU after AECOPD. Mortality in our 
group of patients was comparable to the overall mortality 
data for AECOPD in hospitalized patients, but significantly 
lower than the mortality of patients treated in an ICU, pos-
sibly due to better care provided at the tertiary care ICU 
specialized for respiratory disorders.
Different factors are associated with survival after AECOPD. 
McGhan et al (6) showed that long-term survival after se-
vere COPD exacerbations was associated with age, sex, 
prior hospitalizations, and comorbidities, including weight 
loss and pulmonary hypertension. In a study by Seneffe et 
al (15), variables associated with hospital mortality were 
age, weight, dysfunction of respiratory and other organs, 
and length of hospital stay before ICU admission, while re-
spiratory physiological variables (respiratory rate, serum 
pH, Paco2, Pao2, and alveolar-arterial difference in partial 
pressure of oxygen) were associated with a 6-month mor-
tality. Connors et al (13) reported that survival time was 
associated with disease severity, BMI, age, previous func-
tional status, Pao2/FIO2, congestive heart failure, serum al-
bumin, and cor pulmonale. In our patients, survival time 
was independently associated with monocyte count, LDH 
serum level, comorbidities including malignant disease 
and hypertension, and BMI.
Readmissions of patients hospitalized for AECOPD are fre-
quent and occur in approximately 60% of patients in the 
first year after the incident hospitalization (16). AECOPD ac-
celerates the decline of lung function, deteriorates quality 
of life and health status, and increases mortality (13,17,18). 
The strongest predictors of AECOPD recurrence are previ-
ous frequent exacerbations (18). Other identified risk fac-
tors include poor lung function, poor physical status (16), 
older age (19), poor quality of life (20), hypercapnia, and 
pulmonary hypertension (21). Our results are somewhat 
different, independently associating time to first read-
mission with Paco2 on admission, pH on the second 
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day, and levels of fibrinogen, proteins, and alpha 2 globu-
lins. The number of readmissions was independently asso-
ciated with age, neutrophil count, CAD, and levels of so-
dium and bilirubin.
COPD patients often have associated diseases that sig-
nificantly affect their management and prognosis (22). In 
our study, patients with AECOPD in need for IMV had sig-
nificantly lower RBC counts, hemoglobin, hematocrit, bili-
rubin, albumin, and A/G ratio, and significantly increased 
troponin and alpha 1 globulin levels, but IMV was indepen-
dently associated only with low albumin, low serum chlo-
ride, and low hemoglobin.
Anemia is often a comorbidity in COPD patients and its 
prevalence ranges from 12.3% up to 23%, being even high-
er in AECOPD (up to 50%), and is directly associated with 
negative outcomes and death (23-26). In our study, almost 
a third of patients had anemia, with more than half of them 
requiring IMV in comparison with 9.5% of those without 
anemia. In patients with severe COPD, anemia is associated 
with shorter survival, frequent hospitalizations, and longer 
hospital stay in comparison with patients without anemia 
(27). Anemic COPD patients have increased serum eryth-
ropoietin, indicating erythropoietin resistance that can be 
explained by inflammatory mechanisms (24). In a recent 
study in patients with AECOPD, C reactive protein, inter-
leukin-6, tumor necrosis factor, and erythropoietin were 
found to be significantly higher at the time of hospitaliza-
tion when compared with values at the time of AECOPD 
resolution (28).
Increased respiratory load associated with AECOPD in-
creases the need for oxygen and aggravates anemia, fur-
ther reducing muscle strength, worsening hypoxemia, 
with anemia further reducing oxygen delivery to periph-
ery, all leading to early anaerobic metabolism ultimately re-
sulting in respiratory collapse (29,30). Correction of anemia 
significantly reduces minute ventilation, respiratory load, 
and the possibility of weaning from IMV (27,31).
Lower concentrations of serum proteins have already been 
identified as predictors of poor outcome in AECOPD pa-
tients (14,32,33). Clinically significant threshold for mortal-
ity in the study of Gunen et al (14) was below 2.5 g/L. In our 
study only 3 (4.8%) patients had albumin below 2.5 g/dL 
and two of them were on IMV.
The prevalence of elevated troponin level in AECOPD is 
common, ranging from 18% up to 74% (34). Elevated 
troponin levels often indicate the existence of a cardiac in-
jury in AECOPD patients, associated with higher mortality 
(34-36). The study by Noorain et al (37) showed that 38% of 
patients had elevated troponin I, which was closely associ-
ated with ICU admission and mechanical ventilation. There 
are several causes, including hypoxia, which can lead to 
cardiac injury associated with AECOPD (34). Increased left 
ventricle afterload due to negative intrathoracic pressure is 
one of them (38). During exacerbations of COPD, alveolar 
hypoxia and the consequent increase in pulmonary vascu-
lar resistance lead to a deterioration of pulmonary hyper-
tension and overload of the right heart (38). This can also 
be the consequence of a pulmonary embolism, not a rare 
cause of clinical deterioration and breathlessness in COPD 
patients, often remaining unrecognized (39). Also, cardio-
vascular disease is a frequent comorbidity and a significant 
cause of morbidity and mortality in COPD patients (40-44). 
In patients with AECOPD and an elevated troponin I level, 
coronary angiography confirmed ischemic heart disease in 
67%, and 38.6% required a coronary revascularization (42). 
In our patients, additional diagnostic evaluation (echocar-
diography, coronary angiography, and CT pulmonary an-
giography) was performed to exclude acute coronary inci-
dent or pulmonary embolism.
The limitations of our study are a relatively small number 
of patients and its retrospective design, which leave room 
for a possible bias. On the other hand, 95% CIs for all sig-
nificant predictors of outcomes had narrow intervals well 
away from the margin of no effect. Also, as COPD patients 
have many comorbidities affecting survival, it would be 
important to analyze the causes of death. However, in our 
study only the date of death was available for all deceased 
due to the common practice that autopsy is not manda-
tory even for the patients who died in hospitals. As this is 
a retrospective study of associations, ie, level of evidence 
4, our results may be useful for generating hypothesis and 
should be further corroborated by interventional studies 
focused on the modifiable risk factors for negative out-
comes and death.
To summarize, we found that anemia, hypoalbuminemia 
and elevated troponin levels were risk factors for respira-
tory failure with the need for IMV in patients with severe 
AECOPD. Determination of simple parameters including 
hematologic parameters, albumin, and troponin, can iden-
tify a group of COPD patients with the highest risk for dete-
rioration requiring more intensive monitoring and admis-
sion to the ICU. Identification of high-risk COPD patients at 
the beginning of hospital treatment may lead to an appro-
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priate and timely treatment, which may have a significant 
effect on the outcome in these patients.
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